Jack Hoppin
Chief Executive Officer Ratio Therapeutics
Dr. Jack Hoppin is the Chairman and CEO of Ratio Therapeutics, a Boston-based company specializing in the development of targeted radiopharmaceuticals for cancer treatment. With over two decades of experience in biotechnology and precision medicine, Dr. Hoppin co-founded Invicro, and has held leadership roles at Konica Minolta Precision Medicine, Bioscan, Inc. and Emit Imaging. He earned his PhD in Applied Mathematics from the University of Arizona and continued his training as an Alexander von Humboldt Post-Doctoral Fellow at the Research Center Juelich. In his upcoming session, “Radiopharmaceutical Recap: Landscape Updates, Major Milestones & Trends for the Year(s) Ahead,” Dr. Hoppin will share insights from his extensive experience in advancing radiopharmaceuticals.
Seminars
- Validating tumor-to-healthy expression, prevalence, & heterogeneity to confirm the target is sufficiently selective and consistent to progress
- Assessing accessibility, internalization, replenishment, & density to prove the target can support meaningful radionuclide delivery
- Defining the minimum in vitro, in vivo & imaging evidence to make earlier, higherconfidence target go/no-go decisions